125 related articles for article (PubMed ID: 31246208)
21. New carborane-based compounds for boron neutron capture therapy: binding and toxicity of ANC-1, DAC-1 and B-Et-11-OMe in cultured human glioma and mouse melanoma cells.
Lindström P; Olsson P; Malmqvist J; Pettersson J; Lemmen P; Werner B; Sjöberg S; Olin A; Carlsson J
Anticancer Drugs; 1994 Feb; 5(1):43-52. PubMed ID: 8186429
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of Novel Carborane-Containing Derivatives of RGD Peptide.
Vakhrushev AV; Gruzdev DA; Demin AM; Levit GL; Krasnov VP
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110700
[TBL] [Abstract][Full Text] [Related]
23. Amphiphilic Polycarbonates from Carborane-Installed Cyclic Carbonates as Potential Agents for Boron Neutron Capture Therapy.
Xiong H; Wei X; Zhou D; Qi Y; Xie Z; Chen X; Jing X; Huang Y
Bioconjug Chem; 2016 Sep; 27(9):2214-23. PubMed ID: 27548011
[TBL] [Abstract][Full Text] [Related]
24. (2,2':6',2' '-Terpyridine)platinum(II) complexes containing (thioalkyl)dicarba-closo-dodecaborane(12) ligands.
Todd JA; Turner P; Ziolkowski EJ; Rendina LM
Inorg Chem; 2005 Sep; 44(18):6401-8. PubMed ID: 16124820
[TBL] [Abstract][Full Text] [Related]
25. Dicarba-closo-dodecaboranes as a pharmacophore. Novel potent retinoidal agonists.
Endo Y; Iijima T; Kagechika H; Ohta K; Kawachi E; Shudo K
Chem Pharm Bull (Tokyo); 1999 Apr; 47(4):585-7. PubMed ID: 10319433
[TBL] [Abstract][Full Text] [Related]
26. Novel carboranyl amino acids and peptides: reagents for antibody modification and subsequent neutron-capture studies.
Varadarajan A; Hawthorne MF
Bioconjug Chem; 1991; 2(4):242-53. PubMed ID: 1772906
[TBL] [Abstract][Full Text] [Related]
27. Boron neutron capture therapy of cancer: current status and future prospects.
Barth RF; Coderre JA; Vicente MG; Blue TE
Clin Cancer Res; 2005 Jun; 11(11):3987-4002. PubMed ID: 15930333
[TBL] [Abstract][Full Text] [Related]
28.
Gruzdev DA; Telegina AA; Levit GL; Krasnov VP
J Org Chem; 2022 Apr; 87(8):5437-5441. PubMed ID: 35377641
[TBL] [Abstract][Full Text] [Related]
29. Carborane-based design of a potent vitamin D receptor agonist.
Otero R; Seoane S; Sigüeiro R; Belorusova AY; Maestro MA; Pérez-Fernández R; Rochel N; Mouriño A
Chem Sci; 2016 Feb; 7(2):1033-1037. PubMed ID: 28808527
[TBL] [Abstract][Full Text] [Related]
30. Liposome formulations of o-carborane for the boron neutron capture therapy of cancer.
Olusanya TOB; Calabrese G; Fatouros DG; Tsibouklis J; Smith JR
Biophys Chem; 2019 Apr; 247():25-33. PubMed ID: 30797076
[TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of boron containing monosaccharides by the hydroboration of d-glucal for use in boron neutron capture therapy (BNCT).
Itoh T; Tamura K; Ueda H; Tanaka T; Sato K; Kuroda R; Aoki S
Bioorg Med Chem; 2018 Dec; 26(22):5922-5933. PubMed ID: 30420329
[TBL] [Abstract][Full Text] [Related]
32. Neutron-capture therapy of human cancer: in vitro results on the preparation of boron-labeled antibodies to carcinoembryonic antigen.
Mizusawa E; Dahlman HL; Bennett SJ; Goldenberg DM; Hawthorne MF
Proc Natl Acad Sci U S A; 1982 May; 79(9):3011-4. PubMed ID: 6953444
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and in vitro evaluation of boronated uridine and glucose derivatives for boron neutron capture therapy.
Tjarks W; Anisuzzaman AK; Liu L; Soloway AH; Barth RF; Perkins DJ; Adams DM
J Med Chem; 1992 May; 35(9):1628-33. PubMed ID: 1578491
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of an o-Carboranyl Derivative of 4-[5-(4-Methyl-1-piperazinyl)-2,5'-bi-1H-benzimidazol-2'-yl]phenol.
Argentini M; Dos Santos DF; Weinreich R; Hansen HJ
Inorg Chem; 1998 Nov; 37(23):6018-6022. PubMed ID: 11670736
[TBL] [Abstract][Full Text] [Related]
35. Intracellular delivery and passive tumor targeting of a self-assembled nanogel containing carborane clusters for boron neutron capture therapy.
Kawasaki R; Sasaki Y; Akiyoshi K
Biochem Biophys Res Commun; 2017 Jan; 483(1):147-152. PubMed ID: 28039054
[TBL] [Abstract][Full Text] [Related]
36. The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide.
Michiue H; Sakurai Y; Kondo N; Kitamatsu M; Bin F; Nakajima K; Hirota Y; Kawabata S; Nishiki T; Ohmori I; Tomizawa K; Miyatake S; Ono K; Matsui H
Biomaterials; 2014 Mar; 35(10):3396-405. PubMed ID: 24452095
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and evaluation of cyclic RGD-boron cluster conjugates to develop tumor-selective boron carriers for boron neutron capture therapy.
Kimura S; Masunaga S; Harada T; Kawamura Y; Ueda S; Okuda K; Nagasawa H
Bioorg Med Chem; 2011 Mar; 19(5):1721-8. PubMed ID: 21315608
[TBL] [Abstract][Full Text] [Related]
38. Boron neutron capture therapy of brain tumors: an emerging therapeutic modality.
Barth RF; Soloway AH; Goodman JH; Gahbauer RA; Gupta N; Blue TE; Yang W; Tjarks W
Neurosurgery; 1999 Mar; 44(3):433-50; discussion 450-1. PubMed ID: 10069580
[TBL] [Abstract][Full Text] [Related]
39. Tumor-specific delivery of BSH-3R for boron neutron capture therapy and positron emission tomography imaging in a mouse brain tumor model.
Iguchi Y; Michiue H; Kitamatsu M; Hayashi Y; Takenaka F; Nishiki T; Matsui H
Biomaterials; 2015 Jul; 56():10-7. PubMed ID: 25934274
[TBL] [Abstract][Full Text] [Related]
40. Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT).
Thirumamagal BT; Zhao XB; Bandyopadhyaya AK; Naranyanasamy S; Johnsamuel J; Tiwari R; Golightly DW; Patel V; Jehning BT; Backer MV; Barth RF; Lee RJ; Backer JM; Tjarks W
Bioconjug Chem; 2006; 17(5):1141-50. PubMed ID: 16984121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
